ANI Pharmaceuticals is a cheaply valued specialty generics business (forward P/E 7.1x) with 26% growth, strong cash conversion and a perfect four-quarter beat streak, but supplier concentration and a confirmed downtrend limit near-term conviction.
Thesis pillars
- Strong Growth Low Valuation→Stable
- Earnings Beat Streak↓Deteriorating
- High Cash Conversion Wide Moat→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 27, 2026
ANI Pharmaceuticals, Inc. (ANIP) Stock Analysis
Recovery setup · Inst Constrain edge
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $72.28, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers.
ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceuticals through Rare Disease (Cortrophin Gel, ILUVIEN, YUTIQ), Generics (120+ products), and Brands (12 branded NDAs) segments from three facilities in Minnesota and New Jersey. The company acquired Alimera... Read more
Hold if already holding. Not a fresh buy at $72.28, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers. Chart setup: Death cross but MACD improving, RSI 58. Maintain position. Not compelling to add more. Score 6.8/10, moderate confidence.
Passes 5/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and SEC filing concern and earnings proximity 0d<=7d. Suitability: aggressive.
About ANI Pharmaceuticals, Inc.
About ANI Pharmaceuticals, Inc.
Cortrophin Gel, an ACTH therapy with FDA approvals for autoimmune indications including MS, RA, and nephrotic syndrome, generated a significant portion of ANI Pharmaceuticals' net product revenues in 2025. The company expanded its Rare Disease portfolio in September 2024 with the acquisition of Alimera Sciences, adding ILUVIEN — which received an expanded FDA label for NIU-PS in March 2025 in addition to its existing DME indication — and YUTIQ. Three manufacturing facilities in Baudette, Minnesota and East Windsor, New Jersey support oral solid dose, semi-solid, and potent product manufacturing.
ANI Pharmaceuticals earns revenue through three channels: Rare Disease branded products distributed via specialty pharmacy networks, branded legacy drugs sold through wholesale channels, and generics sold to pharmacy chains, wholesalers, and hospitals. Cortrophin Gel's specialty pharmacy distribution network was expanded in the second quarter of 2025 with a prefilled syringe format approved by FDA in February 2025. Cortrophin Gel and ILUVIEN cannot be manufactured in ANI's own facilities; both depend exclusively on third-party contract manufacturers. API for each product is generally qualified from a single source, with supplier changes requiring an FDA Prior Approval Supplement that can take six to nine months, and up to 19 months if additional data are needed. The Generics and Other segment holds 120+ products with an expected 10 to 15 new launches annually, while the Brands portfolio includes twelve branded NDAs including Atacand, Vancocin, and Inderal LA.
Show full overview
Manufacturing dependency is structural for the two highest-revenue products: Cortrophin Gel and ILUVIEN are produced exclusively by third-party contract manufacturers under arrangements ANI cannot directly control, and the API for each product qualifies from a single source. Any change to an API supplier requires an FDA Prior Approval Supplement taking six to nineteen months, creating a long replacement timeline if a sole-source supplier fails. The 10-K identifies Cortrophin Gel and ILUVIEN supply disruptions as potential material adverse effects, and notes that if a contract manufacturer fails to meet regulatory requirements, the company may be unable to commercialize these products with no rapid substitute readily available.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From ANI Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated Nov 2, 2026Recent Developments — ANI Pharmaceuticals, Inc.
Latest news
- NEWS Why Is ANI Pharmaceuticals (NASDAQ:ANIP) Near Lows Despite Strong Results? - Kalkine Media — Kalkine Media Nov 2, 2026 negative
- NEWS ANI Pharmaceuticals (ANIP) Slips to $72.00 as Shares Test Support Zone - Institutional Flow Picks - https://www.siam.in/ — https://www.siam.in/ Nov 1, 2026 negative
- NEWS ANI Pharmaceuticals (ANIP) Set to Post Quarterly Earnings on Thursday - MarketBeat — MarketBeat Oct 29, 2026 neutral
- NEWS ANIP Q3'26 Earnings: revenue estimate is 280.26M USD - TradingView — TradingView Oct 29, 2026 neutral
- NEWS ANIP|ANI Pharmaceuticals Inc|Price:81.750|Chg%:+0.710 - TradingKey — TradingKey Jul 30, 2026 neutral
Latest item Nov 2, 2026 · Generated 2026-11-04T11:29:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMProductCortrophin Gel10-K Item 1A: 'a significant portion of our net product revenues were derived from the sale of Cotrophin Gel...sales of Cortrophin Gel will continue to account for a significant portion of our net product revenues'
- HIGHSuppliersingle-source API per product10-K Item 1A: 'we qualify only a single source of API for use in each product due to the cost and time required to validate and qualify a second source of supply'
- HIGHSupplierCortrophin Gel and ILUVIEN contract manufacturers10-K Item 1: 'We do not have in-house manufacturing capabilities for the production of Cortrophin Gel or ILUVIEN, and thus we depend, and expect to continue to depend, exclusively on third-party contract manufacturers'
Material Events(8-K, last 90d)
- 2026-04-07Item 4.01HIGHANI Pharmaceuticals dismissed EisnerAmper LLP as independent registered public accounting firm, effective April 1, 2026. Audit Committee approved the dismissal. No disagreements on accounting principles or practices cited. No successor named.SEC filing →
- 2026-05-21Item 5.02LOWStockholders approved Amended and Restated 2022 Stock Incentive Plan at ANI Pharmaceuticals' 2026 Annual Meeting on May 21, 2026. Routine compensatory arrangement approval; no officer departure or appointment.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $72.28, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers. Chart setup: Death cross but MACD improving, RSI 58. Maintain position. Not compelling to add more. Analyst target $92.03 (+27.3%), stop $68.50 (−5.5%), A.R:R 5.2:1. Score 6.8/10, moderate confidence.
Analyst target: $92.03 (+27.3% upside). Analyst target $92.03 (+27.3%), stop $68.50 (−5.5%), A.R:R 5.2:1. Stop-loss: $68.50.
Concentration risk — Supplier: single-source API per product; Concentration risk — Supplier: Cortrophin Gel and ILUVIEN contract manufacturers; Leverage penalty (D/E 1.0): -0.5.
ANI Pharmaceuticals, Inc. trades at a P/E of 15.3 (forward 7.1). TrendMatrix value score: 8.9/10. Verdict: Hold.
15 analysts rate ANIP, with a consensus score of 4.1/5. 9 analysts publish price targets averaging $106.
What does ANI Pharmaceuticals, Inc. do?ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceuticals through Rare Disease (Cortrophin Gel,...
ANI Pharmaceuticals develops, manufactures, and commercializes pharmaceuticals through Rare Disease (Cortrophin Gel, ILUVIEN, YUTIQ), Generics (120+ products), and Brands (12 branded NDAs) segments from three facilities in Minnesota and New Jersey. The company acquired Alimera Sciences in September 2024, adding an ophthalmic retinal franchise and international commercial operations in Germany, UK, Portugal, and Ireland. A significant portion of net product revenues is derived from Cortrophin Gel.